Previous close | 2.7100 |
Open | 2.8000 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 2.7300 - 2.8400 |
52-week range | 1.8000 - 6.0000 |
Volume | |
Avg. volume | N/A |
Market cap | 10.811M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groupsContinuous development of the geneType portfolioA deep pipeline of new unique and ground-breaking tests Strong Global Academi
MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will be a world first; including over 200
Looking at Genetic Technologies Limited's ( ASX:GTG ) insider transactions over the last year, we can see that insiders...